160 related articles for article (PubMed ID: 12851475)
1. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
3. The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.
de Winter JP; van der Weel L; de Groot J; Stone S; Waisfisz Q; Arwert F; Scheper RJ; Kruyt FA; Hoatlin ME; Joenje H
Hum Mol Genet; 2000 Nov; 9(18):2665-74. PubMed ID: 11063725
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Wang Z; Li M; Lu S; Zhang Y; Wang H
Cancer Biol Ther; 2006 Mar; 5(3):256-60. PubMed ID: 16418574
[TBL] [Abstract][Full Text] [Related]
5. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
6. FANCF methylation contributes to chemoselectivity in ovarian cancer.
Olopade OI; Wei M
Cancer Cell; 2003 May; 3(5):417-20. PubMed ID: 12781358
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.
Narayan G; Arias-Pulido H; Nandula SV; Basso K; Sugirtharaj DD; Vargas H; Mansukhani M; Villella J; Meyer L; Schneider A; Gissmann L; Dürst M; Pothuri B; Murty VV
Cancer Res; 2004 May; 64(9):2994-7. PubMed ID: 15126331
[TBL] [Abstract][Full Text] [Related]
9. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
[TBL] [Abstract][Full Text] [Related]
10. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
12. The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen F
Leuk Lymphoma; 2015 Mar; 56(3):755-62. PubMed ID: 24996439
[TBL] [Abstract][Full Text] [Related]
13. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway.
Medhurst AL; Huber PA; Waisfisz Q; de Winter JP; Mathew CG
Hum Mol Genet; 2001 Feb; 10(4):423-9. PubMed ID: 11157805
[TBL] [Abstract][Full Text] [Related]
14. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes.
Yamashita T; Nakahata T
Int J Hematol; 2001 Jul; 74(1):33-41. PubMed ID: 11530803
[TBL] [Abstract][Full Text] [Related]
15. RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.
Xie J; Kim H; Moreau LA; Puhalla S; Garber J; Al Abo M; Takeda S; D'Andrea AD
J Clin Invest; 2015 Apr; 125(4):1523-32. PubMed ID: 25751062
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of fanconi anemia.
Taniguchi T; Dandrea AD
Int J Hematol; 2002 Feb; 75(2):123-8. PubMed ID: 11939257
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and the sensitive cell.
Bagby GC; Olson SB
Nat Med; 2003 May; 9(5):513-4. PubMed ID: 12724761
[No Abstract] [Full Text] [Related]
18. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
19. A Boolean network model of the FA/BRCA pathway.
Rodríguez A; Sosa D; Torres L; Molina B; Frías S; Mendoza L
Bioinformatics; 2012 Mar; 28(6):858-66. PubMed ID: 22267503
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the Fanconi anemia pathway by monoubiquitination.
Gregory RC; Taniguchi T; D'Andrea AD
Semin Cancer Biol; 2003 Feb; 13(1):77-82. PubMed ID: 12507559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
